stockrowVir Biotechnology, Inc.
VIRVir Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $68.6 million, down 7.61% from fiscal 2024.
- Revenue
- −178.3%
- EPS
- +51.4%
- Free cash flow
- +36.8%
Quarter to September 2026, against a year earlier
Follow VIR
Alert me
Vir Biotechnology, Inc. (VIR) EV/FCF
As of 11 November 2026, Vir Biotechnology, Inc. (VIR) trades at a EV/FCF of −12.4×. Over the past ten years it has ranged from −71.2× (September 2021) to 4.1× (May 2022); the current reading is higher than 28% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −0.9× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.2× | (71.78%) |
| FY2022 | 0.6× | — |
| FY2021 | −68.0× | — |
| FY2020 | −12.4× | — |
| FY2019 | 0.1× | (95.95%) |
| FY2018 | 1.4× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | −10.1× | — |
| Jun 2026 | −5.8× | — |
| Mar 2026 | −1.9× | — |
| Dec 2025 | −0.9× | — |
| 28 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| ZYME Zymeworks Inc. compare | −17.4× |
| TRAX First Tracks Biotherapeutics, Inc. compare | −14.6× |
| NAMS NewAmsterdam Pharma Company N.V. compare | −12.8× |
| VIR Vir Biotechnology, Inc. | −12.4× |
| REPL Replimune Group, Inc. compare | −8.6× |
| IMNM Immunome, Inc. compare | −7.2× |
| BHVN Biohaven Ltd. compare | −4.9× |
| RXRX Recursion Pharmaceuticals, Inc. compare | −4.4× |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.7× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on VIR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement